For the past decades, blockade of the renin-angiotensin system (RAAS) using angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists has been the standard of antihypertensive care which improve both renal and cardiovascular outcomes in patients with type 2 diabetes (T2D) [2,3]. Here, ACE is linked to type 2 diabetes mellitus.